Thalidomide (Contergan/Distaval) — the “Safe” Sedative That Deformed 10,000 Babies and Rewrote Drug Law

When Chemie Grünenthal launched thalidomide in West Germany as Contergan on 1 October 1957, it sold the compound as a sedative so safe that a child could swallow the whole bottle without harm, marketed it without prescription, and promoted it specifically to pregnant women for morning sickness; the documented record shows that the drug was instead one of the most powerful human teratogens ever distributed, and that it reached pregnant patients across roughly 46 countries before any company or regulator had required a single study of its effects on the unborn. Thalidomide, sold in the United Kingdom and Commonwealth by the Distillers Company as Distaval and in dozens of other markets under more than forty trade names, was withdrawn in West Germany on 26 November 1961 after the Hamburg pediatrician Widukind Lenz formally linked it to an epidemic of phocomelia — infants born with foreshortened or flipper-like limbs.

The gap between the promise and the harm was total and structural. Grünenthal advertised the drug as “completely safe” and “non-toxic,” yet it had performed no studies of the drug crossing the placenta and no testing in pregnant animals before approval; the standard toxicity tests of the era, measured by acute lethal dose, registered thalidomide as remarkably benign precisely because its danger lay not in poisoning the patient but in disrupting the developing embryo during a narrow window early in pregnancy. The verdict here is therefore plain at the outset: a non-prescription product advertised as harmless to mother and child was, in fact, causing catastrophic limb, ear, eye, and internal-organ malformations, and the absence of reproductive-safety testing meant the signal could only surface after thousands of affected infants had already been born.

The reckoning that followed reshaped how the world licenses medicines. William McBride’s letter in The Lancet on 16 December 1961 and Lenz’s epidemiological work converted a cluster of “mysterious” birth defects into a recognized drug catastrophe. In the United States, the drug was never approved: FDA medical reviewer Frances Oldham Kelsey had refused to clear Richardson-Merrell’s application (trade name Kevadon) for over a year, repeatedly demanding the safety data the company could not supply. The episode produced the Kefauver-Harris Amendments, signed on 10 October 1962, which for the first time required proof of efficacy as well as safety and established the modern controlled-trial regime.

The Contergan name became the permanent byword for what happens when marketing velocity, over-the-counter access, and the complete absence of reproductive testing converge on a vulnerable population — and for how a single regulator’s refusal can avert a national disaster.

DES (diethylstilbestrol) — the Useless Pregnancy Estrogen That Gave Daughters Vaginal Cancer

When the U.S. Food and Drug Administration issued its Drug Bulletin on 25 November 1971 declaring diethylstilbestrol contraindicated in pregnancy, it was retracting an indication it had blessed twenty-four years earlier for a drug that had never been shown to work — and the trigger was not a failure of efficacy but a cancer in a generation that had been exposed before birth. DES, the first orally active synthetic estrogen, was synthesized in 1938 in the Middlesex Hospital laboratory of Sir Edward Charles Dodds in London, deliberately left unpatented, and promoted from the mid-1940s by the Harvard husband-and-wife team of George and Olive Smith as a means of preventing miscarriage by “building up” placental hormones. The gap between that promise and the documented record is among the widest in pharmaceutical history: the drug did not prevent miscarriage, and it carried a harm that would not become visible for roughly two decades.

The signal arrived in April 1971, when Arthur Herbst, Howard Ulfelder, and David Poskanzer published a case-control study in The New England Journal of Medicine reporting eight cases of clear-cell adenocarcinoma of the vagina in young women aged 15 to 22 — a tumor so rare in that age group that a cluster of eight was itself an anomaly. Seven of the eight mothers had taken DES while pregnant; only one of thirty-two matched controls had. The association was overwhelming, with the odds of chance occurrence below one in one hundred thousand. The mechanism was transplacental: a drug given to the mother had reached across the placenta and altered the developing reproductive tract of the fetus, with the consequence emerging only at puberty.

The verdict is therefore plain at the outset. An estimated five to ten million Americans — pregnant women and the children born of those pregnancies — were exposed to DES between roughly 1940 and 1971 on the strength of an indication that controlled trials had already shown to be useless. As early as 1953, William Dieckmann’s randomized, double-blind study at the University of Chicago Lying-In Hospital had demonstrated that DES did not reduce miscarriage, premature birth, or neonatal death; prescribing continued for eighteen more years regardless. The drug was not so much a wonder therapy that went wrong as an unproven one that was never stopped.

What remains is a two-generation injury with a long tail. DES daughters carry roughly forty times the baseline risk of clear-cell adenocarcinoma, develop it at a rate near 1 in 1,000, and face elevated rates of infertility, ectopic pregnancy, premature delivery, and breast cancer; DES sons and even a third generation have shown reproductive anomalies. The episode became the founding case study of the transplacental carcinogen and a standing rebuke to the idea that a drug’s safety can be judged only in the patient who swallows it.